Arsenic trioxide oral - Orsenix

Drug Profile

Arsenic trioxide oral - Orsenix

Alternative Names: ORH-2014

Latest Information Update: 16 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orsenix
  • Class Anti-inflammatories; Antineoplastics; Arsenicals; Ischaemic heart disorder therapies; Oxides; Small molecules
  • Mechanism of Action Apoptosis stimulants; Endothelial cell modulators; Immunostimulants; Thioredoxin reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute promyelocytic leukaemia; Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase I Haematological disorders

Most Recent Events

  • 14 Jun 2018 Interim pharmacokinetics and adverse events data from a phase I trial in Haematological disorders presented at the 23rd Congress of the European Haematology Association (EHA-2018)
  • 02 Dec 2016 Phase-I clinical trials in Haematological disorders (Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT03048344)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top